Abstract
Acetylcholinesterase inhibitors are regarded as the most promising approach to treat Alzheimer’s disease (AD). However, their anticipated side effects limit their usage. Present investigations involved the incorporation of the newly synthesized 2-naphthol derivatives (PP-81 and PP-84) into solid lipid nanoparticles (SLNs) to improve their accessibility to the brain and enhance the levels of acetylcholine. Drug loaded SLNs of PP-81 and PP-84 showed that average particle size of 138 nm and 186 nm, positive zeta potential and total drug content of 86.13 ± 0.49 % w/v and 81.18 ± 0.78 % w/v respectively were obtained using microemulsification technique. The particles were found to be spherical in shape, with high drug entrapment (91.28 ± 0.14 % w/w, PP-81 and 70.94 ± 0.59 % w/w, PP-84) at 10 % drug loading. Confirmation of SLNs formation was performed using DSC and PXRD studies. In in vitro release study diffusion phenomenon was predominant and was prolonged up to 24 h. Elevated plus maze test was carried out to evaluate memory acquisition and retention; post treatment with SLNs and respective free drugs in scopolamine induced spatial memory deficit in mice. Results indicated a significant increase (p < 0.05) in percentage retention of memory and learning with PP-81 and PP- 84 SLNs respectively at 20 mg/kg. It can be an optimized potential therapeutic and brain targeting approach for the treatment of AD.
Keywords: Alzheimer’s disease, acetylcholinesterase inhibitors, microemulsification method, solid lipid nanoparticles, DSC, PXRD, elevated plus maze.
Current Drug Therapy
Title:Newly Synthesized Acetylcholinesterase Inhibitors for Alleviating Alzheimer’s Disease using Solid Lipid Nanoparticles
Volume: 9 Issue: 2
Author(s): Rohit Makkar, Paramveer Singh, Chhanda C. Danta, Vandita Kakkar, Indu P. Kaur and Poonam Piplani
Affiliation:
Keywords: Alzheimer’s disease, acetylcholinesterase inhibitors, microemulsification method, solid lipid nanoparticles, DSC, PXRD, elevated plus maze.
Abstract: Acetylcholinesterase inhibitors are regarded as the most promising approach to treat Alzheimer’s disease (AD). However, their anticipated side effects limit their usage. Present investigations involved the incorporation of the newly synthesized 2-naphthol derivatives (PP-81 and PP-84) into solid lipid nanoparticles (SLNs) to improve their accessibility to the brain and enhance the levels of acetylcholine. Drug loaded SLNs of PP-81 and PP-84 showed that average particle size of 138 nm and 186 nm, positive zeta potential and total drug content of 86.13 ± 0.49 % w/v and 81.18 ± 0.78 % w/v respectively were obtained using microemulsification technique. The particles were found to be spherical in shape, with high drug entrapment (91.28 ± 0.14 % w/w, PP-81 and 70.94 ± 0.59 % w/w, PP-84) at 10 % drug loading. Confirmation of SLNs formation was performed using DSC and PXRD studies. In in vitro release study diffusion phenomenon was predominant and was prolonged up to 24 h. Elevated plus maze test was carried out to evaluate memory acquisition and retention; post treatment with SLNs and respective free drugs in scopolamine induced spatial memory deficit in mice. Results indicated a significant increase (p < 0.05) in percentage retention of memory and learning with PP-81 and PP- 84 SLNs respectively at 20 mg/kg. It can be an optimized potential therapeutic and brain targeting approach for the treatment of AD.
Export Options
About this article
Cite this article as:
Makkar Rohit, Singh Paramveer, C. Danta Chhanda, Kakkar Vandita, P. Kaur Indu and Piplani Poonam, Newly Synthesized Acetylcholinesterase Inhibitors for Alleviating Alzheimer’s Disease using Solid Lipid Nanoparticles, Current Drug Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574885509666140804222101
DOI https://dx.doi.org/10.2174/1574885509666140804222101 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Energy Balance by Peptides: A Review
Current Protein & Peptide Science Roles of Orexins and Orexin Receptors in Central Regulation of Feeding Behavior and Energy Homeostasis
CNS & Neurological Disorders - Drug Targets Hypoglycemia Induces Tau Hyperphosphorylation
Current Alzheimer Research Targeting Sphingosine-1-Phosphate Receptors in Cancer
Anti-Cancer Agents in Medicinal Chemistry Study of Male Sex Hormone Levels in Male Egyptian Children with Beta-Thalassemia: Correlation with Iron load
Endocrine, Metabolic & Immune Disorders - Drug Targets Preface
Current Psychopharmacology Dihydrocodeine as an Opioid Analgesic for the Treatment of Moderate to Severe Chronic Pain
Current Drug Metabolism GPCR Drug Discovery: Novel Ligands for CNS Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Drugs Polypharmacology by In Silico Methods: New Opportunities in Drug Discovery
Current Pharmaceutical Design Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics
Current Molecular Medicine D-Serine Regulation: A Possible Therapeutic Approach for Central Nervous Diseases and Chronic Pain
Mini-Reviews in Medicinal Chemistry Transconjunctival Sutureless 23-gauge Vitrectomy for Diabetic Retinopathy. Review
Current Diabetes Reviews New Kid on the Block: Does Histamine Get Along with Inflammation in Amyotrophic Lateral Sclerosis?
CNS & Neurological Disorders - Drug Targets Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design Neuromodulators and Therapeutic Targets in Neuropathic Pain: From Molecules to Man
CNS & Neurological Disorders - Drug Targets Structural Analysis and Comparison of Active Site Architecture from Ancient Bacteria to Human Phosphatases: A Novel Approach to Identification of Lead Compounds with Increased Specificity and Potency for Drug Discovery
Current Physical Chemistry Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
Current Pharmaceutical Design Psychotropics and Fertility
Current Women`s Health Reviews Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets